Results 301 to 310 of about 274,076 (393)

Febrile neutropenia - Can it be Cyclic neutropenia?

Pediatric Oncall, 2017
Sajini Mary Varughese, Rajeev Ramachandran   +1 more
openaire   +1 more source

Diagnosis and management of primary autoimmune neutropenia in children: insights for clinicians

Therapeutic Advances in Hematology, 2015
P. Farruggia, C. Dufour
semanticscholar   +1 more source

JAK–STAT inhibitory effect of IN‐115314, a novel small molecule inhibitor, and pharmacokinetic/pharmacodynamic study in canine

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose The JAK–STAT signalling pathway has been extensively spotlighted as a therapeutic target for various diseases. This study assessed the inhibitory effects of a novel small molecule, IN‐115314, on JAK–STAT pathway. Experimental Approach The IC50 values of IN‐115314 for JAK1–pSTAT3 and JAK2–pSTAT5 were determined in canine ...
Jae‐Hun Ahn, Joohwan Kim, Jina Kwak, Jooil Kim, Na‐Young Lee, Heejin Choi, Hee‐Jin Bae, So‐Hyun Cho, Sung‐Gu Jung, Hye‐Mi Kwon, Euna Kwon, Donghyun Kim, Myeongjoong Kim, Daseul Yoon, Seohyun Kim, Bongtae Kim, Byeong‐Cheol Kang   +16 more
wiley   +1 more source

T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS. [PDF]

Cancers (Basel)
Mancuso K, Talarico M, Manzato E, Barbato S, Tacchetti P, Zamagni E, Cavo M.   +6 more
europepmc   +1 more source

PI3Kδ Inhibitor Parsaclisib in Japanese Patients With Relapsed or Refractory Follicular Lymphoma

Cancer Science, EarlyView.
CITADEL‐213 evaluated the efficacy and safety of parsaclisib (PI3Kδ inhibitor) in Japanese patients with relapsed or refractory follicular lymphoma (R/R FL). The objective response rate was 88.1%, with 23.8% of patients experiencing a complete response and 64.3% experiencing a partial response; treatment‐emergent adverse events led to parsaclisib ...
Noriko Fukuhara, Isao Yoshida, Takuro Ishiguro, Katsuya Fujimoto, Junya Kuroda, Toshiki Uchida, Ryusuke Yamamoto, Yoshiaki Ogawa, Yasushi Hiramatsu, Toshiro Ito, Seiichiro Katagiri, Tomonori Nakazato, Kazumi Suzukawa, Kenzo Kinami, Mi Zhou, Eiju Negoro   +15 more
wiley   +1 more source

Delphi consensus on the management of adverse events in patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan. [PDF]

Oncologist
Valsecchi AA, Pisegna S, Antonuzzo A, Arpino G, Bianchini G, Biganzoli L, Colloca GF, Criscitiello C, Danesi R, Fabi A, Giusti R, Pau L, Di Maio M, Santini D.   +13 more
europepmc   +1 more source

Phase I study of pomalidomide in relapsed or refractory Waldenström macroglobulinaemia

British Journal of Haematology, EarlyView.
Karan L. Chohan, Donna M. Weber, Lei Feng, L. Michael Wang, Sattva S. Neelapu, Jasper Olsem, Ralph J. Johnson, Claudia Morales de Partovi, Robert Z. Orlowski, Sheeba K. Thomas   +9 more
wiley   +1 more source

Dual Targeting of Aurora‐A and Bcl‐xL Synergistically Reshapes the Immune Microenvironment and Induces Apoptosis in Breast Cancer

Cancer Science, EarlyView.
The combination of the Aurora‐A kinase inhibitor MLN8237 and the BH3 mimetic ABT263 enhanced anti‐tumor immunity by boosting CD8+ T cells and natural killer cells, while reducing immunosuppressive cells in the tumor microenvironment. It induced apoptosis via extrinsic and intrinsic pathways with minimal toxicity, offering a promising therapeutic ...
Mingxue Liu, Jing Guo, Weiyong Liu, Zhenye Yang, Fazhi Yu   +4 more
wiley   +1 more source

The Role of Initial Neutropenia and Neutrophil Dynamics in Personalizing Chemotherapy for Platinum-Resistant Ovarian Cancer. [PDF]

Medicina (Kaunas)
Dragomir RD, Negru AG, Mercioni MA, Popovici D, Săftescu S, Blidari AR, Curcă RO, Sas I.   +7 more
europepmc   +1 more source